EVALUATION OF THE PHARMACOTHERAPEUTIC EFFICACY OF GLUTARGIN AND ERBISOL IN THE INTERRECURRENT PERIOD OF CHRONIC ECZEMA
DOI:
https://doi.org/10.11603/bmbr.2706-6290.2020.2.11383Keywords:
chronic eczema, treatment, antioxidants, adaptogensAbstract
Summary. The need for constant and long-term monitoring of patients with chronic eczema (CE) at the level of primary health care highlights the need to improve treatment in the period between relapses. It is important to determine the pharmacotherapeutic effects of antioxidants and adaptogenic agents, especially in relation to the formation of metabolic compensatory reactions in patients with chronic eczema, as a guarantee of prolongation of clinical remission of chronic eczema.
The aim of the study – to evaluate the effectiveness of differentiated therapeutic complexes at the level of the system of nonspecific immune defense and oxidative homeostasis in patients with chronic eczema in the interrecurrent period.
Materials and Methods. The study involved 75 patients with CE, who were divided into three groups depending on the composition of differentiated therapeutic complexes (DTC), and in the interrelapse period was treated, in particular in patients of the clinical group 1 (CG1) used the Glutargin drug (0.25 mg three times) per day for 3 weeks), in the group 2 (CG2) – Erbisol drug (daily 2.0 ml intramuscularly for three weeks), in the treatment of patients of the group 3 (CG3) used Glutargin and Erbisol drugs. The pharmacotherapeutic efficacy of DTC was assessed by indicators of the state of the OH system and non-specific immune system protection.
Results. The pharmacotherapeutic effects of Glutargin and Erbisol in patients with chronic eczema in the interrecurrent period were studied and proved to be the most effective in a single therapeutic complex, which allows to achieve adaptive and compensatory reactions of the oxidative homeostasis system and the immune system patients with simultaneous formation of metabolic reserves of adaptation.
Conclusions. It was found that the use of Glutargin slightly increases the frequency of persons with functional compensation and decreases the proportion of patients with metabolic imbalance reactions (p> 0.05); the generalized efficiency index for clinical group (CG1) is 1.11. When using Erbisol the frequency of persons with functional compensation significantly increases and the proportion of patients with metabolic imbalance reactions decreases (p<0.05); the generalized efficiency index for CG2 is 1.38. When using the complex (Glutargin and Erbisol) significantly increases the frequency of persons with functional compensation (p <0.05) and decreases the proportion of patients with metabolic imbalance reactions (p <0.01); the generalized efficiency index for CG3 is 1.71. It was found that when using all three therapeutic complexes, the frequency of patients with immunoregulatory compensation increases, the proportion of patients with immunoregulatory imbalance reactions decreases (p <0.05).
References
Abakumova YuV. [Physiological and pathological free radical oxidation: essence, recognition technique, theoretical and practical significance]. Vrachevaniye i yego metodologiya, Saratov. 1996; 33. Russian.
Ardamatskiy NA, Abakumova YuV, Korsunova YeN. [Method for determining physiological and pathological peroxidation]. Ekogen. 1994;4: 9. Russian.
Methkal Ahmad Mahmoud Mamduh, Kuts, LV, Cherkashyna LV. Classification and clinical phenomenology of compensatory reactions of contact-protective systems in patients with eczema. Azerbaijan Medical Journal. 2020;2: 39-46. DOI: 10.34921/amj.2020.2.006
Byelenichev IF, Levytskyy YeL, Kovalenko, SI. [Products of free radical peroxidation and methods of their identification]. Sovremennye problemy toksykologii. 2002;4: 9-18. Ukrainian.
Gavrilov BV, Mishkorudnaya MI. [SF -– metric determination of the content of GPR in blood plasma]. Laboratornoye delo. 1983;3: 33-6. Russian.
Gavrilov BV, Gavrilova AR, Mazhul LM. [Analysis of methods for determining the products of lipid peroxidation in blood serum by the test with TBA]. Voprosy meditsinskoy khimii. 1987;33(1): 118-23. Russian.
Gorbunov NV. [Activation of nitric oxide production mediated by metabotropic glutamate receptors in primary cell cultures – cerebellar grains]. Byulleten eksperimentalnoy biologii i meditsiny. 1995;7: 40-8. Russian.
Gurevich VS, Kontoridinova KN, Shapilina SV. [Comparative analysis of two methods for determining the activity of superoxide dismutase]. Laboratornoye delo. 1990;4: 44-7. Russian.
Dubinina YeYe, Burmistrov SO, Khodov DA, Porotov IS. [Oxidative modification of human serum proteins. Methods for its determination]. Voprosy meditsinskoy khimii. 1995;42(1): 24-6. Russian.
Kostyuk VA, Potapovich AI, Kovalova ZhV. [A simple and sensitive method for the determination of superoxide dismutase based on the oxidation reaction of quercetin]. Voprosy meditsinskoy khimii. 1990;32: 88-91. Russian.
Kosukhin AB, Akhmetova BS. [Extraction of lipids with a mixture of heptane isopropanol for the determination of DC]. Laboratornoye delo. 1987;5: 335-7. Russian.
Lemeshko VV, Nykytchenko YuV, Evych YV. [Glutathione peroxidase and glutathione transferase]. Ukrainskyi biokhimichnyi zhurnal. 1987;8, 59-7. Ukrainian.
Lishchuk VA. [Informatization of clinical medicine / Klin. informatics and telemedicine]. Klinicheskaya informatika i telemeditsina. 2004;1: 7-13. Russian.
Prokhorova MI. Biochemical research methods. [Методы биохимических исследований] Leningrad: LGU (Leningrad State University); 1982. Russian.
Cherkashyna LV, Bilovol AM, Shklyar SP. Contact-protective systems in systemic dermatoses: condition and pathogenetic correction in eczema (population-etiological features, lipid peroxidation, oxidative/antioxidant system, nonspecific immune protection. [Контактно-захисні системи при системних дерматозах: стан та патогенетична корекція при екземі (популяційно-етіологічні особливості, перекисне окислення ліпідів, оксидантно- антиоксидантна система, неспецифічний імунний захист, імуномодулятори)] FOP Shlëmych S.F.; 2008. Ukrainian.
Cherkashyna LV. [Research of risk factors, development of criteria and substantiation of the algorithm for predicting eczema at the stage of primary care]. Ukrainskyi zhurnal medytsyny, biolohii ta sportu. 2018;3(6/15): 180-7. Ukrainian. DOI: https://doi.org/10.26693/jmbs03.06.180
Cherkashyna LV. [Assessment of the quality of medical care at the initial stage of its provision to patients with eczema: a study of the volume and assessment of the adequacy of treatment and prevention measures]. Aktualni pytannia suchasnoi medytsyny: Visnyk Ukrainskoi medychnoi stomatolohichnoi akademii. 2018;4 (64): 80-3. Ukrainian. DOI: https://doi.org/10.31718/2077-1096.18.4.80
